Keywords: Russia, Pharmaceutical industry, Structural defects, Clinical trials

Structural defects holding back growth of Russia's pharmaceutical industry

Article | 03 December 2012

Despite having grown significant since 2009 and set to be worth $10.7 million by 2014, there are some crucial structural defects in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in